1,821,739 research outputs found
Neu Reekie, #UntitledTwo "20 Years of Real Life (Album version)"
No full textContribution to accompanying downloadable double album in Neu Reekie, #UntitledTwo.
“Imagine 30 recording artists coming together to donate tracks to a blisteringly hot compilation album. Imagine it being given away for free with an anthology of cutting edge poetry. This is #UntitledTwo - the latest project from Neu! Reekie! - #UntitledTwo is a unique Neu! Reekie! collaboration between poets & musicians and is published by Polygon Book.”
Neu Reekie burst onto the cultural scene, in Edinburgh (then later Glasgow and the Highlands) in 2010, but can trace its intellectual heft back to the Scottish counterculture of the 1970s. Co-editor of this collection, Kevin Williamson, founded radical literary magazine Rebel Inc alongside Sandie Craigie in 1992. They published early work by Irvine Welsh, and, after being taken under the wing of Canongate, reissued work by Glaswegian Alexander Trocchi under the imprint Rebel Inc Classics.
Poetry Anthology and Double Compilation Album
34 Writers, 30 Bands / Singer-Songwriters
Special Edition Poetry Anthology and downloadable double albu
Leona (Woeszner) Neu Collection
Full text linkBiographical materials, scanned photographs, correspondence, coffin plates, hymnals, theology, and other books acquired by Leona (Woeszner) Neu from Ashley, ND and the surrounding area.Biographical materials, scanned photographs, correspondence, coffin plates, hymnals, theology, and other books acquired by Leona (Woeszner) Neu from Ashley, ND and the surrounding area
[Almanac of the New Braunfelser Newspaper for 1943]
No full textThe 1943 almanac from the Neu-Braunfelser Zeitung
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
Full text linkBackground: P53, egfr and her-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance. Methods: Published studies that investigated the association between p53, egfr and her-2/neu status and survival were identified. Meta-analysis was performed using a dersimonian-laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis. Results: A total of 62 studies were included for p53, 15 for egfr and 20 for her-2/neu. P53, egfr and her-2/neu status had a modest effect on overall survival (Pooled hr 1.47, 95% Ci 1.33-1.61 For p53; Hr 1.65, 95% Ci 1.25-2.19 For egfr and hr 1.67, 95% Ci 1.34-2.08 For her-2/neu). Meta-regression analysis for p53 showed that figo stage distribution influenced study outcome. For egfr and her-2/neu, considerable publication bias was present. Conclusions: Although p53, egfr and her-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies. British journal of cancer ( 2009) 101, 149-159. Doi: 10.1038/Sj.Bjc.6605112 Www.Bjcancer.Com published online 9 june 2009 (C) 2009 Cancer research uk
Interview with Rupert Neu, Cohocton, NY, 1988
No full textThis is an interview with Rupert Neu who plays songs and talks about where he learned them.https://knightscholar.geneseo.edu/kimball-interviews/1043/thumbnail.jp
Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Full text linkTrastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas. After phase I and II trials, several phase III studies of trastuzumab alone or in combination with various chemotherapies were conducted. Patients with HER2/neu overexpression levels of 3+ determined by immunohistochemical assay or gene amplification (fluorescence in situ hybridization) derive most clinical benefit from trastuzumab. Taking into consideration efficacy and side effect profile, the combination of trastuzumab and paclitaxel showed an improvement of all clinical parameters, including overall survival, for the first time in the history of palliative breast cancer therapy. The application of trastuzumab has meanwhile become an established part of systemic therapy of metastastic breast cancer, and excellent data of its application in the adjuvant setting now exist (NSABP-B31, NCCTG-N9831, HERA), with significantly better relapse-free survival in the treatment arms with trastuzumab. Ongoing trials investigate the role of trastuzumab in the neoadjuvant setting. Trastuzumab is generally well tolerated. Cardiotoxicity is the main concern, thus monitoring of cardiac function is recommended
Heimgarten, Terrain-Gesellschaft Neu-Westend, Böttcher
No full textHEIMGARTEN, TERRAIN-GESELLSCHAFT NEU-WESTEND, BÖTTCHER
Heimgarten, Terrain-Gesellschaft Neu-Westend, Böttcher ( -
CCL2 production associated with MMTV-neu-driven tumors.
No full text(A) CCL2 concentrations were measured by ELISA in sera from 4 wild type and 6 neu+ mice at the indicated ages. The difference between wild type and tumor bearing mice was significant by two-way ANOVA (p B) Cell lines were developed from neu+, neu+/CCL2-/-, and neu+/CCR2-/- mice. CCL2 released into the culture medium by 106 cells over a 72 hr period was measured by ELISA.</p
Edward Neu, Dalton Wells Camp, general views
No full textImage shows a general view of the area of land near the Dalton Wells CCC Camp, near Moab.Edward Neu, the donor of this photo, was enrolled in the CCC from 1936 to 1937 at the Dalton Wells Camp. The Dalton Wells CCC Camp worked in conjunction with the U. S. Division of Grazing (DG or G)
- …
